Drugs / PYC-003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06714006 | Apr 2025 → Nov 2028 expected | autosomal dominant polycystic kidney disease | PYC Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PYC-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06714006 ↗ |
| Modality | Oligonucleotide (other) | “A peptide-phosphorodiamidate morpholino oligonucleotide conjugate administered as a single intravenous infusion” NCT06714006 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT06714006 ↗ |